PRRT2 and cancer: Although PKC inhibitors block the pro-proliferative and apoptotic functions of PKC, which are significantly activated in cancer settings, other cellular signals (e.g., AKT) that promote proliferation and are anti-apoptotic, may be able to replace the PKCs.